Cardiology Pharmaceuticals

PCSK9 Inhibitors: Sooner or Later?

Sooner certainly seems to be better than later when it comes to treating LDL-C levels with the PCSK9 inhibitor evolocumab, and according to a recent JACC study, that’s especially true for older patients.

  • People aged ≥75 years make up ~65% of all deaths linked to cardiovascular disease, with age being one of the primary risk factors for ASCVD.
  • However, the potential for low effectiveness and unfavorable safety profiles has led to fewer guidelines for treating older patients using non-statin lipid lowering drugs.

Putting age before beauty, researchers conducted a prespecified analysis of the FOURIER-OLE study and found that among roughly 6.6k patients, evolocumab reduced the study’s composite primary endpoint of CV death and complications by twice as much in older patients (≥75) than in younger ones (<75) compared to placebo.

  • Earlier evolocumab initiation reduced the rate of CV death, MI, stroke, hospitalization, or revascularization by 21% in older patients and 14% in younger patients.
  • Evolocumab achieved over 2x greater risk reductions in older patients (5.4% vs. 2.3%), leading to a far lower number needed to treat to avoid one event (19 vs. 44).
  • Incidence rates of safety events appeared similar across both age groups, suggesting that the PCSK9i is safe for older patients.

Despite evolocumab’s effectiveness, current AHA/ACC guidelines don’t list non-statin lipid lowering agents as a potential prevention for ASCVD, leading to less prescriptions and availability for these therapies.

  • At least insurance isn’t an issue. With evolocumab now covered under Medicare, the drug’s once $600 list price isn’t what most patients are paying for it.

The Takeaway

When you consider that older patients see nearly twice the benefit with PCSK9 inhibitors, guidelines that shy away from non-statin LDL-C therapy might not make sense. After all, it’s not just about increasing patient lifespans when healthspan is on the table too.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiac Imaging June 16, 2025

Beyond Hardware: Is AI the Answer to Making Cardiac Imaging more Accessible? June 16, 2025

Sponsored by Philips Healthcare Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment. Today, software and AI are driving the next leap in cardiac image quality and motion control – offering […]

Cardiology Pharmaceuticals June 12, 2025

FDA Approves a New BP Triple Polypill June 12, 2025

Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]

Cardiology Pharmaceuticals June 12, 2025

Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery  June 12, 2025

The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.   Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized.  […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!